https://www.selleckchem.com/pr....oducts/arry-380-ont-
ms of operative time, blood loss and LOS without differences in major complications and R0 resection rate. Surgical society guidelineshave recommendedchangingthe treatment strategy for early esophageal cancer during the novel coronavirus (COVID-19) pandemic. Delaying resection canallow for interimdisease progression, but the impact of this delay on mortality is unknown. The COVID-19 infection rate at which immediate operative risk exceeds benefit is unknown. We sought to model immediate versus delayed surgical resection in a T1
Like
Comment
Share
